University of California, San Francisco

Siemens, Siemens Healthineers and UCSF research partnership proves significant energy, cost and emission reduction in MRI machine operation

Retrieved on: 
Tuesday, April 25, 2023
General Health, Environment, Health, Technology, Software, San Francisco, Urbanization, Partnership, University, Carbon footprint, Hospital, University of California, San Francisco, Radiology, Research, Medical imaging, EBIT, Carbon, MRI, Magnetic resonance imaging, Siemens Healthineers, Climate change, MD, UCSF, Deep Decarbonization Pathways Project, Ecosystem, Transport, Siemens Energy

The Siemens Healthineers team deployed new, greener radiology scanner technology while also exploring ways to reduce standby energy consumption of MRI scanners.

Key Points: 
  • The Siemens Healthineers team deployed new, greener radiology scanner technology while also exploring ways to reduce standby energy consumption of MRI scanners.
  • Due to their energy intensive operation, imaging equipment and particularly more efficient MRI operation can present a significant opportunity to reduce a hospital’s power usage, costs, and carbon footprint.
  • Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare.
  • In addition, Siemens holds a minority stake in Siemens Energy, a global leader in the transmission and generation of electrical power.

Zerigo 2.0 is Here: Psoriasis and Eczema Now Treatable at Home in Half the Time

Retrieved on: 
Tuesday, April 25, 2023
Injection, RNS, Dermatitis, Health, University of California, San Francisco, Psoriasis, Quality of life, Research, Privacy, Light, LED, Patient, UCSF, Physician, SAN, Ecosystem, System, FDA, Ampere-hour, Skin, Safety, Body surface area, Pharmaceutical industry, Medical device, Nursing, Light therapy

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Zerigo Health, today announces the launch of the Zerigo 2.0 ecosystem - the newest iteration of its digital health platform for the treatment and management of chronic skin conditions like eczema and psoriasis to employers, health plans, and their providers across the U.S. The Zerigo Health ecosystem works together to support a patient's success, including a personal, clinical-grade, FDA-cleared, handheld, Smart UVB Light Therapy device, Zerigo smartphone app, access to ZerigoCare™ Guides for personal coaching and support, and access to a network of virtual care providers for clinical assessment and ongoing continuity of care. Using the Zerigo device, patients living with chronic psoriasis and eczema can safely treat themselves at home without invasive injections, doctor visits, pills or topicals.

Key Points: 
  • Using the Zerigo device, patients living with chronic psoriasis and eczema can safely treat themselves at home without invasive injections, doctor visits, pills or topicals.
  • "Psoriasis and eczema can substantially impair a patients' physical health, quality of life and work productivity," said Dr. Tina Bhutani, dermatologist and psoriasis specialist practicing at UC San Francisco (UCSF) Health and advisor to Zerigo Health.
  • "Zerigo Health allows psoriasis and eczema patients to treat themselves at home without inconvenient doctor visits, topicals, pills or invasive injections.
  • Optimizations to the Zerigo device LED light source enables the treatment of twice the body surface area in half the treatment time, relative to previous device designs.

BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer

Retrieved on: 
Monday, April 24, 2023
San Francisco, Biologics license application, Late Phases, University, Verastem Oncology, Therapy, Senior, Brainstorm, File, Harvard University, Advisory Committee, EVP, University of California, San Francisco, Stanford University, Merck Group, CMO, Patient, INSEAD, Pain management, Yale University, Faculty, Growth, Merck, Hospital, Rare, Albert Einstein College of Medicine, Merck Serono, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, ALS, Neurology, BLA, Food, Pfizer, Management, Pharmaceutical industry, Biogen

NEW YORK, April 24, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (EVP, CMO), effective May 1, 2023. Dr. Taylor will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.

Key Points: 
  • NEW YORK, April 24, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (EVP, CMO), effective May 1, 2023.
  • Dr. Taylor will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.
  • "Kirk's appointment is the first important step in strengthening a targeted, capability build to expand our medical, regulatory and advocacy teams in preparation for anticipated growth," said Chaim Lebovits, President and CEO of BrainStorm.
  • We are thrilled to welcome Kirk to BrainStorm and look forward to the contributions he will make."

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, JDRF, Angeles volunteer association, University of Colorado School of Medicine, Drug development, University, National Jewish Health, T1D, Pediatrics, University of California, San Francisco, INVU (album), Rheumatology, CMO, Multiple sclerosis, Biomarker, Bangladesh Technical Education Board, TCR, Merck & Co., Foundation for the National Institutes of Health, MS, Science, Regulatory T cell, Third Rock Ventures, Patient, UCSF, Autoimmune disease, Lightspeed Venture Partners, Biology, Knowledge, Therapy, IND, Autoimmunity, Inflammation, Pharmaceutical industry, Nursing, Genentech

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
  • Dr. Dragone brings to Abata extensive experience in preclinical and early clinical development and autoimmune medicine.
  • I’m thrilled he’ll be joining us to advance this work.”
    Dr. Dragone most recently served as chief medical officer at Sonoma Biotherapeutics.
  • Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases.

Sugar Rush: Scientists Discover Key Role of Glucose in Brain Activity

Retrieved on: 
Tuesday, April 18, 2023
Learning, Neuron, CRISPR, Human, Galactose, Alzheimer's disease, Department of Neurology, Xuanwu hospital, Glucose, University of California, San Francisco, Brain, Research, Cell, Doctor of Philosophy, Protein, Parkinson's disease, Glycolysis, Animal, Metabolism, MD, UCSF, Myenteric plexus, SAN, Blood, Chaumeil, Mouse, Liver, William Ewart Gladstone, Ageing, Gladstone Institutes, IPS, Neurology, Disease, Cell Reports, Medical imaging, Medical device

SAN FRANCISCO, April 18, 2023 /PRNewswire/ -- The human brain has a sweet tooth, burning through nearly one quarter of the body's sugar energy, or glucose, each day. Now, researchers at Gladstone Institutes and UC San Francisco (UCSF) have shed new light on exactly how neurons—the cells that send electrical signals through the brain—consume and metabolize glucose, as well as how these cells adapt to glucose shortages.

Key Points: 
  • Previously, scientists had suspected that much of the glucose used by the brain was metabolized by other brain cells called glia, which support the activity of neurons.
  • Past studies have established that the brain's uptake of glucose is decreased in the early stages of neurodegenerative diseases like Alzheimer's and Parkinson's.
  • Scientists have long debated what happens to glucose in the brain, and many have suggested that neurons themselves don't metabolize the sugar.
  • They engineered the animals' neurons— but not other brain cell types—to lack the proteins required for glucose import and glycolysis.

HI-Bio Appoints Industry Veterans Uptal Patel, M.D., as Chief Medical Officer and Sunil Agarwal, M.D., as Board Member

Retrieved on: 
Tuesday, April 18, 2023
Juno, Duke University, Gilead Sciences, Executive, Tufts University School of Medicine, Biotechnology, DSM-IV codes, University, Metabolism, Nephrology, University of California, San Francisco, ARCH Venture Partners, University of California, San Diego, Genentech, Child, AstraZeneca, Children's National Hospital, Research and development, Biochemistry, Duke University School of Medicine, Development, Partner, Patient, Manufacturing execution system, SAN, Agrawal, Clinical research, Kidney, Medicine, Neuroscience, City of Hope National Medical Center, Faculty, Juno Therapeutics, Therapy, Cornell University, ERT (company), Kidney disease, Disease, Pharmaceutical industry, Vaccine, Nursing, Management, Ultragenyx, Chemistry, Sofinnova, Research

The company also announced that Sunil Agarwal, M.D., has been appointed to the Company's Board of Directors.

Key Points: 
  • The company also announced that Sunil Agarwal, M.D., has been appointed to the Company's Board of Directors.
  • "In particular, his deep experience in nephrology will help us accelerate our clinical programs in Primary Membranous Nephropathy, and across the immune-mediated disease landscape.
  • "This is a very exciting time to join HI-Bio, following the recent positive results from two studies of felzartamab," said Uptal Patel, M.D., Chief Medical Officer at HI-Bio.
  • Agarwal was most recently Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology.

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

Retrieved on: 
Thursday, April 13, 2023
San Francisco, KOL, University, EPP, University of California, San Francisco, AURORA, Research, IRON, Patient, Erythropoietic protoporphyria, Porphyria, Paris Diderot University, Epidemiology, Pharmaceutical industry, Gastroenterology

The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.

Key Points: 
  • The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.
  • Intended for investors and other interested audiences, the virtual event will feature presentations from leading porphyria experts, who will provide a disease overview and discuss epidemiology, pathophysiology, disease burden, and unmet need associated with EPP.
  • A live webcast of the event will be available in the Events and Presentations section of the Investor page of Disc’s website (https://ir.discmedicine.com/).
  • Please register for the event on the Events and Presentations page of Disc’s website or by clicking this link .

Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026

Retrieved on: 
Tuesday, April 4, 2023
Chief scientific officer, DMT, Weill Institute for Cell and Molecular Biology, Depression, University, University of California, San Francisco, Neuroimaging, MDD, Patient, The Retreat, Psychiatry, Behavioural sciences, Phase, Safety, Major depressive disorder, Pharmaceutical industry, N, Neurology

LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive six-month data from the Company’s Phase IIa clinical trial of SPL026.

Key Points: 
  • LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive six-month data from the Company’s Phase IIa clinical trial of SPL026.
  • New data from the Phase IIa trial shows that among the patients who had achieved remission within three months with SPL026, 64% sustained remission to six months.
  • The trial investigated the efficacy and safety of 21.5mg intravenous (“IV”) SPL026 with supportive therapy in 34 patients with moderate/severe MDD.
  • Dr. Carol Routledge, Chief Medical & Scientific Officer said: “With our ongoing analyses of the Phase IIa trial data, we are increasingly encouraged by the treatment potential of SPL026.

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Retrieved on: 
Friday, March 31, 2023
San Francisco, Retina, Surgeon, Depression, University, University of California, San Francisco, ADHD, Cancer, Toxicity, Research, Medicine, CNS, Central nervous system, Trial of the century, Net, Suretrack Contracts Services, Stanford University Medical Center, MDD, Patient, UCSF, Medical Center, Grammatical mood, Bupropion, CSMC, Phase, Visual acuity, Deficit, Safety, Pharmaceutical industry, Cryptocurrency, Medical device, Phase II

FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.

Key Points: 
  • FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.
  • Our operating expenses were $15,797,780 in the year ended December 31, 2022, as compared to $12,056,679 in the year ended December 31, 2021.
  • The net loss was $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021.
  • “We are delighted with our remarkable accomplishments and meaningful progress in 2022,” said Dr. Howard Doong, M.D., Ph.D., Chief Executive Officer of ABVC BioPharma.

Children’s Hospital Los Angeles Names Kelly M. Johnson, PhD, RN, NEA-BC, as Senior Vice President and Chief Nursing Officer

Retrieved on: 
Wednesday, April 12, 2023
General Health, Hospitals, Health, Practice Management, Nursing, Magnet, Children's Hospital Los Angeles, Psychology, Operation, Health care, University, Senior, Education, MSN, Hospital, CHLA, CNO, University of California, San Francisco, Stanford University, Neuroscience, Nancy, Multimedia, Research, Rehabilitation, Children's Hospital, Doctor of Philosophy, Children's Hospital Colorado, Administration, School, Retirement, UC, Family Health Care Decisions Act, Physician, Child, RN, Director of Administration and Management (Department of Defense), Frontier Nursing Service, Trauma, Social work, University of Northern Colorado, Safety

Following a comprehensive national search, Children's Hospital Los Angeles (CHLA) has named Kelly M. Johnson, PhD, RN, NEA-BC, as Senior Vice President and Chief Nursing Officer.

Key Points: 
  • Following a comprehensive national search, Children's Hospital Los Angeles (CHLA) has named Kelly M. Johnson, PhD, RN, NEA-BC, as Senior Vice President and Chief Nursing Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230412005115/en/
    Children's Hospital Los Angeles has named Kelly M. Johnson, PhD, RN, NEA-BC, as Senior Vice President and Chief Nursing Officer.
  • “I am thrilled to welcome Kelly to the team and would also like to extend my deep gratitude to our former Chief Nursing Officer and Chief Clinical Officer Nancy Lee for her nearly seven years of service and leadership.
  • Johnson’s hiring follows the retirement of Nancy Lee, RN, MSN, Senior Vice President, Chief Clinical Officer and Chief Nursing Officer.